Michael Makris/LinkedIn
Apr 3, 2026, 15:51
Michael Makris: Approved but Unavailable Hemophilia B Gene Therapy Remains Out of Reach
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn:
”If you are hoping to have gene therapy for hemophilia B you will have to wait, as currently there is no product available for use outside China.
Hemgenix is the only FDA/EMA approved gene therapy that is commercially available, but the company making it has announced that they do not have any product due to a manufacturing issue. They stress that this is not a safety issue.
The Chinese product is only approved for use in China, and it is at least theoretically possible to travel to have the infusion in Shanghai.”
Other posts featuring Michael Makris on Hemostasis Today.
-
Jun 4, 2026, 11:57José María Bastida Bermejo: IPDs Help to Better Understand Platelet Biogenesis and Function
-
Jun 4, 2026, 11:07Cristina Pecorilla: PSG6 and A New Approach to Cancer-Associated Thrombosis
-
Jun 4, 2026, 10:55Jacqui McCallum: Stroke Foundation Brings Stroke Advocacy to State Parliaments
-
Jun 4, 2026, 10:47Eugene Tang: Do Dementia-Predicting Scores Work for Stroke Patients?
-
Jun 4, 2026, 10:392026 National Stroke Awards Nominations Are Now Open – Stroke Foundation
-
Jun 4, 2026, 10:29Juliana Ferreira: Blogging Stroke on Exploring Early Markers of Post-Stroke Cognitive Decline
-
Jun 4, 2026, 10:20John Noble: My First Shadowing Experience in Hematology
-
Jun 4, 2026, 10:19Why Resilience Matters for Plasma-Derived Medicinal Products – PPTA Europe
-
Jun 4, 2026, 05:42Subramamyam Penubaku: Early Recognition and Risk-Based Management of Acute Pulmonary Embolism